Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Thursday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($0.01) per share and revenue of $310.3580 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Madrigal Pharmaceuticals Stock Down 1.9%

Shares of NASDAQ:MDGL opened at $464.71 on Tuesday. The company has a market cap of $10.55 billion, a price-to-earnings ratio of -35.72, a PEG ratio of 6.60 and a beta of -1.01. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.44 and a quick ratio of 3.26. The firm has a fifty day moving average price of $529.58 and a two-hundred day moving average price of $479.38. Madrigal Pharmaceuticals has a one year low of $265.00 and a one year high of $615.00.

Analyst Ratings Changes

Several research firms recently issued reports on MDGL. Wolfe Research set a $579.00 target price on Madrigal Pharmaceuticals in a research note on Tuesday, January 6th. TD Cowen reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Monday, January 12th. Oppenheimer boosted their price objective on shares of Madrigal Pharmaceuticals from $600.00 to $650.00 and gave the stock an “outperform” rating in a report on Thursday, November 20th. Canaccord Genuity Group raised their price target on Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Citizens Jmp increased their price target on shares of Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $654.73.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, Director Paul A. Friedman sold 24,520 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $522.39, for a total transaction of $12,809,002.80. Following the transaction, the director directly owned 187,164 shares of the company’s stock, valued at approximately $97,772,601.96. This trade represents a 11.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Shannon T. Kelley sold 692 shares of Madrigal Pharmaceuticals stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $497.36, for a total value of $344,173.12. Following the completion of the transaction, the general counsel owned 8,481 shares in the company, valued at $4,218,110.16. This represents a 7.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 101,495 shares of company stock valued at $54,568,691. 21.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MDGL. Quarry LP purchased a new stake in Madrigal Pharmaceuticals in the third quarter valued at approximately $39,000. Johnson Financial Group Inc. acquired a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at approximately $50,000. Kestra Investment Management LLC purchased a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at $85,000. Smartleaf Asset Management LLC increased its stake in shares of Madrigal Pharmaceuticals by 50.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 187 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 63 shares during the period. Finally, Virtus Advisers LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter worth $210,000. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.